| Particulars (Rupees in Crores.) | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 |
|---|---|---|---|---|
Gross Sales | 2,065.96 | 2,052.2 | 2,027.04 | 2,151.14 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 2,065.96 | 2,052.2 | 2,027.04 | 2,151.14 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 45.1 | 23.72 | 19.16 | 14.87 |
Total Income | 2,111.06 | 2,075.92 | 2,046.2 | 2,166.01 |
Total Expenditure | 1,850.68 | 1,803 | 1,929.49 | 2,151.74 |
PBIDT | 260.38 | 272.92 | 116.71 | 14.27 |
Interest | 9.68 | 24.92 | 24.81 | 25.8 |
PBDT | 250.71 | 247.99 | 91.9 | -11.54 |
Depreciation | 84.52 | 68.93 | 65.5 | 60.14 |
Minority Interest Before NP | 0 | 0 | 0 | 0 |
Tax | 40.21 | 40.7 | 14.13 | 61.42 |
Deferred Tax | -89.93 | 10.51 | -143.26 | 21.65 |
Reported Profit After Tax | 215.92 | 127.86 | 155.53 | -154.74 |
Minority Interest After NP | 3.12 | 2.48 | 3.15 | 1.68 |
Net Profit after Minority Interest | 212.8 | 125.38 | 152.38 | -156.42 |
Extra-ordinary Items | 13 | 2.64 | 1.13 | 4.32 |
Adjusted Profit After Extra-ordinary item | 199.8 | 122.74 | 151.25 | -160.74 |
EPS (Unit Curr.) | 13.9 | 8.58 | 10.65 | -10.93 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 |
Equity | 30.62 | 30.62 | 28.61 | 28.61 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 |
PBIDTM(%) | 12.6 | 13.29 | 5.75 | 0.66 |
PBDTM(%) | - | - | - | - |
PATM(%) | 10.45 | 6.23 | 7.67 | -7.19 |
The organisation is the largest CDMO serving the Indian pharmaceutical industry, with a proven track record and a broad clientele.
The IPO comprised a fresh issue of shares worth ₹680 crore and an offer-for-sale (OFS) of 1.73 crore shares, aggregating ₹1,177 crore.
The IPO consists of a fresh issue of ₹680 crore and an offer for sale (OFS) of up to 1.73 crore shares at a face value of ₹2 each.
On Monday, the business said that it had received ₹829 crore from anchor investors ahead of the public share sale subscription period.
The IPO includes a new issue of 1 Crore shares worth ₹680.00 Crore and an offer for sale of 1.73 Crore shares worth ₹1,176.74 Crore.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
